1222 GMT - Bayer is starting to show some green shoots, with a strong financial performance in the first quarter and improving prospects, Barclays analysts say in a research note. The strong first-quarter momentum for the German group, and especially for its pharma business, could continue into the rest of the year, Barclays says. New drug launches and a robust base business could lead Bayer's pharma business to exceed guidance, Barclays says. Meanwhile, Bayer's crop protection and consumer segments are on track to meet guidance despite some regulatory and profitability pressures, the analysts say. Nevertheless, the company remains in the early stages of its turnaround plan, they add. Barclays lifts its target price on Bayer to 25 euros from 22 euros. Shares rise 0.8% to 24.88 euros. (adria.calatayud@wsj.com)
(END) Dow Jones Newswires
May 27, 2025 08:22 ET (12:22 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。